Fondaparinux
Synonym(s)
Fondaparinux sodium
DefinitionThis section has been translated automatically.
Systemically active heparin analogue (pentasaccharide). Selective factor Xa inhibitor.
Pharmacodynamics (Effect)This section has been translated automatically.
- Antithrombin III (AT III)-mediated selective and reversible inhibition of factor Xa by selective binding to AT III Approximately 300-fold enhancement of AT III-mediated inhibition of factor Xa. Secondarily, the inhibition causes an interruption of the blood coagulation cascade and thus prevents both thrombin formation and thrombus growth. No effect on thrombocytes.
- At therapeutic doses the substance has no effect on routine coagulation parameters, e.g. activated partial thromboplastin time (aPTT), activated coagulation time (ACT), prothrombin time (PT), International Normalized Ratio (INR), bleeding time, fibrinolytic activity.
Cave! The effect of Fondaparinux cannot be antagonized by the antidote protamine, unlike heparins!
IndicationThis section has been translated automatically.
Prophylaxis of venous thromboembolic events. In exceptional cases in patients with intolerance reactions to heparins, low-molecular-weight heparins or heparinoids.
Pregnancy/nursing periodThis section has been translated automatically.
Insufficient data on use in pregnancy. Contraindicated during lactation (preparation passes into breast milk in animal experiments).
Dosage and method of useThis section has been translated automatically.
once/day 2.5 mg s.c.
Cave! Do not inject i.v. or i.m.!
Undesirable effectsThis section has been translated automatically.
Anemia, bleeding in the operating area in postoperative patients, rarely reactions at the injection site.
ContraindicationThis section has been translated automatically.
Hypersensitivity to the substance, active clinically relevant bleeding, bacterial endocarditis, severe renal dysfunction.
PreparationsThis section has been translated automatically.
Arixtra